While ancient civilizations leaned into real-world utilization to understand the impact of botanicals and other therapies, the scientists of the early 20th century conceptualized the idea of a “well controlled” trial, which moved beyond observation into a more rigid clinical setting. Today’s double-blind, placebo-controlled, gold-standard clinical trial methodology is grounded in the idea of centralized medical settings, narrow populations, on-site investigators and a costly operational model. And while it has established important standards for control, measurement and credibility, as with so many aspects of modern life, globalization, technology, and consumer expectations are resetting the bar for how evidence is generated.
Decentralized Clinical Trials (DCTs): Scientific Rigor Meets the Real World
Decentralized clinical trials (DCTs), where the trial takes place outside of a designated clinical site, are the natural evolution of the clinical research infrastructure. They cannot be considered experimental nor can the impact of what they deliver be minimized. While traditional site-based studies have been the de facto approach, the assumption that scientific rigor requires physical control and a centralized environment has been debunked. The first virtual study dates back to 2011, a trial by Pfizer on an overactive bladder treatment.(1) And the COVID-19 pandemic accelerated the expansion of DCTs and moved them into the mainstream.
In 2024, FDA released a guidance document on DCTs,(2) citing multiple potential benefits of remote participation in clinical trials. These include enhanced convenience, and improved participant engagement, recruitment, enrollment, and retention. Significantly, the FDA also noted DCTs are better positioned to obtain a more representative trial population, which can improve the strength and generalizability of the evidence.
Modernization has made it feasible to design remote studies that maintain the critical elements of a gold-standard trial, such as randomization, placebo control, and powered outcomes. In a win-win, the DCT model allows for significantly greater scale and diversity of study population. Ultimately, this permits the ability to generate representative data in the real world while also delivering scientific rigor.
Rigor is Not a Location; It is a Design Principle
Scientific rigor is defined by study design, data quality, validated outcomes, statistical methods, participant experience, and operational control. Utilizing an institutional review board (IRB) ensures the protocol meets standards for participant safety, verifies informed consent, and satisfies regulatory requirements. When purpose-built, DCTs integrate appropriate use of randomization, blinding, data capture, and much more. While all trials are designed to investigate the impact of an intervention on a target population, DCTs expand the pool of possibilities, while making the most of the tools at hand to accomplish the goals.
Why DCTs are Built for Wellness Innovation
In addition, the move to DCTs has added benefits for wellness innovation. It has always been a challenge to take a drug-centric clinical trial model and apply it to the needs of the broader health and nutrition industry. DCTs offer speed, scale, and diversity of population that is required to meet the needs of the dynamic global wellness market.
Real-world relevance is an advantage in the wellness category. Commercial teams are seeking information that answers practical questions and guides go-to-market strategy. Well-designed DCTs can preserve the rigor of a site-based study while improving the external validity; consumers use products in their normal routines, across varied demographics and geographies. If evidence is meant to tell a brand what happens in the real market, then real-world evidence is not noise; it is the setting. This means that companies can use the evidence to make defensible claims, with stronger claims that apply against a broader population.
Scale as a Design Feature
Scale can serve as a unique differentiator in trial design, particularly as wellness products are not binary in their impact. Decentralized trials share the attributes of increased access and participant flexibility; however, as with a site-based approach, the results of a 30-person trial are applicable to that population. DCTs can integrate and explore variation in a much larger population cohort, affording the ability to uncover consumer-relevant dimensions including sex, age, lifestyle, adherence and many more. The extended reach of this large-scale population further allows the use of data analysis to unearth new insights for future exploration, not as endpoints unto themselves, but a starting point for what comes next.
Digital Health Technologies Power DCTs
The DCT model can make use of multiple, validated digital health technologies (DHTs) to capture health outcomes, behavioral data, perceptions, and biomarkers. These may include electronic consent, digital recruitment, automated reminders, remote product fulfilment, validated surveys, connected devices, direct-to-consumer (DTC) biomarker testing, and real-time operational oversight.
By integrating digital tools at the foundation of a DCT, researchers can:
- improve participant recruitment, including speed and diversity of study population;
- improve participant retention by eliminating roadblocks associated with site-based engagement;
- enable remote or online participant consent;
- offer more convenience and control for participants; and
- enable real-time data collection of endpoints, further improving study results.
Further, the DCT model with appropriate DHTs can increase adherence, as participants are taking responsibility for their well-being, proactively engaging with technologies that track the intervention and impact. Ultimately, this combination of customizable study designs, real-world populations, digital check-ins, advanced statistical analysis, machine learning clustering, AI sentiment analysis, and wearables is what allows Radicle Science to generate precision insights rapidly and cost effectively.
The Future of Scalable Evidence Generation
DCTs are more participant-centric and afford researchers the chance to give back actionable data or information to consumers that is relevant to their day-to-day lives. This has the potential to create a community of citizen scientists who are empowered to control their own health and well-being, and collectively share the ability to create a positive future for others.
DCTs and DHTs are reimagining what a clinical trial can be, how to best serve participants, and how to generate more and deeper evidence. Decentralized clinical trials are not only acceptable. They are the future of the scalable evidence-generation engine that will power go-to-market strategy for wellness.
References
Frequently Asked Questions
Are decentralized trials as rigorous as traditional site-based trials?
Yes. Rigor comes from study design, not physical location. When these trials are purpose-built with randomization, placebo control, blinding, and powered outcomes, they meet the same methodological standard as site-based research. The difference is reach, because they deliver that rigor across larger, more representative populations.
What are decentralized trials for wellness and supplement brands?
Decentralized trials let wellness and supplement brands test products in participants’ real lives instead of a centralized clinical site. They use digital tools to recruit, consent, and measure outcomes remotely. For wellness innovation, this means faster studies, more diverse populations, and evidence that reflects how consumers actually use a product.
How do DCTs generate real-world evidence?
DCTs collect data from participants using products in their normal routines, across varied demographics and geographies. This improves external validity, so the results describe what happens in the actual market rather than a narrow lab population. That makes the resulting claims stronger and more defensible.
Do decentralized trials support defensible product claims?
Yes. A well-designed decentralized trial preserves the methodological standards regulators expect, including IRB oversight, informed consent, and validated outcomes. Because the data reflects a broader, more representative population, brands can make claims that apply to more of their actual customers.
How do decentralized trials shorten time to market?
They compress timelines through digital recruitment, remote consent, and real-time data capture, removing the roadblocks that slow site-based studies. Scalable evidence lets commercial teams validate a functional benefit in time for the next label or launch cycle. The result is a go-to-market strategy built on proof rather than assumption.
What digital health technologies do DCTs use?
Common tools include electronic consent, digital recruitment, automated reminders, connected devices and wearables, validated surveys, and direct-to-consumer biomarker testing. These technologies capture outcomes, behavioral data, and biomarkers remotely. Together they enable real-time oversight and precision insights at scale.
